Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose-escalation Study to Assess the Safety of AFM11 (CD19 x CD3 TandAb) in Patients With Relapsed or Refractory Adult B-precursor Acute Lymphoblastic Leukemia

Next Previous
Trial Profile

A Phase I Dose-escalation Study to Assess the Safety of AFM11 (CD19 x CD3 TandAb) in Patients With Relapsed or Refractory Adult B-precursor Acute Lymphoblastic Leukemia

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AFM 11 (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Affimed Therapeutics

    • Most Recent Events

    • 03 Jan 2023 Results (n=16; AFM11-101 and n=17; AFM11-102) assessing the safety of AFM11 in the treatment of patients with B-cell malignancies from NCT02106091 and NCT02848911 studies, published in the Trials.
    • 17 Jun 2019 Status changed from suspended to discontinued.
    • 17 Apr 2019 According to an Affimed N.V media release, the company today announced that it has submitted to the U.S. Food and Drug Administration (FDA) additional information (clinical trial protocol) to Affimed initial response document submitted in early March relating to the previously announced clinical hold on AFM11. Affimed anticipates receiving a response from the FDA regarding the status of the AFM11 clinical program in the second quarter of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top